Risk of Malignancy for a 22mm TI-RADS 4 Thyroid Nodule
A solitary 22mm thyroid nodule classified as TI-RADS 4 carries a malignancy risk of approximately 6-31%, and fine-needle aspiration (FNA) is indicated at this size.
ACR TI-RADS 4 Classification and Risk Stratification
The ACR TI-RADS system assigns points based on five ultrasound features: composition, echogenicity, shape, margin, and echogenic foci. TI-RADS 4 nodules score 4-6 points and are classified as "moderately suspicious" for malignancy 1.
According to the ACR TI-RADS guidelines, FNA is recommended for TR4 nodules ≥15mm 1. Your 22mm nodule exceeds this threshold, making FNA clearly indicated.
Malignancy Risk Data
The malignancy risk for TI-RADS 4 nodules varies across studies but consistently falls in a moderate range:
Prospective validation studies show TI-RADS 4 subdivisions carry different risks:
- TR4a (4 points): 4.8% malignancy
- TR4b (5 points): 30.3% malignancy
- TR4c (6 points): 75.5% malignancy 2
Real-world clinical cohorts demonstrate: A positive predictive value of only 2.8% for TR4 nodules when compared to Bethesda cytology, though this increases to 6.1% when confirmed by surgical histopathology 3
Recent data from indeterminate cytology studies: TR4 nodules with benign cytology (AUS/FN without molecular alterations) show ROM of 10-15%, but this increases to 31-44% when cytology is indeterminate 4
Critical Clinical Considerations
The specific point total within the TR4 category matters significantly. A nodule with 4 points has dramatically lower malignancy risk (5%) compared to one with 6 points (75%) 2. The exact ultrasound features present—particularly hypoechogenicity, irregular margins, microcalcifications, and taller-than-wide shape—are independent predictors of malignancy 5.
Common Pitfalls to Avoid:
- Don't assume all TR4 nodules carry equal risk—the point subtotal (4a vs 4b vs 4c) substantially changes management urgency
- Size alone doesn't determine malignancy—a 22mm TR4 nodule may be less concerning than a 15mm TR5 nodule
- Background Hashimoto's thyroiditis increases malignancy risk to 86.6% for TR4+ nodules, compared to 83.2% without HT, and amplifies the predictive value of calcifications 6
Recommended Management Algorithm
- Perform ultrasound-guided FNA immediately for this 22mm TR4 nodule 1
- Document the specific TR4 subcategory (4a/4b/4c based on exact point total) to refine risk assessment
- Check thyroid antibodies to identify Hashimoto's thyroiditis, which modifies risk stratification 6
- If FNA yields nondiagnostic results (Bethesda I): Repeat FNA is indicated, as TR4 nodules with nondiagnostic cytology carry 5.9% malignancy risk 7
- If FNA yields indeterminate cytology (Bethesda III/IV): Consider molecular testing, though TR4 nodules without molecular alterations still carry 10-15% malignancy risk 4
The ACR TI-RADS system demonstrates superior specificity (73.77%) and overall accuracy (76.14%) compared to alternative systems like EU-TI-RADS, making it the preferred risk stratification tool 5.